Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phyo T Htoo

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
American Journal of Epidemiology|June 4, 2019
Counterpoint: Keeping the Demons at Bay When Handling Time-Varying Exposures-Beyond Avoiding Immortal Person-TimeJessie K Edwards, Phyo T Htoo, Til Stürmer
Annals of Internal Medicine|January 17, 2022
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, Phyo T Htoo, Brendan M Everett, et al.
Journal of the American Heart Association|February 8, 2022
Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart FailurePhyo T Htoo, John Buse, Matthew Cavender, et al.
European Journal of Clinical Pharmacology|May 12, 2016
Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursorsPhyo T Htoo, John B Buse, Mugdha Gokhale, et al.
Epidemiology (Cambridge, Mass.)|July 27, 2019
Renin-Angiotensin-Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare BeneficiariesPhyo T Htoo, Til Stürmer, Michele Jonsson-Funk, et al.
American Journal of Epidemiology|September 3, 2024
A systematic approach to evaluating instrumental variable assumptions: applied example of glucose-lowering medications and risk for hospitalized heart failure in older adultsPhyo T Htoo, Jessie K Edwards, Mugdha Gokhale, et al.
Pharmacoepidemiology and Drug Safety|October 25, 2023
Stratified analysis in comparative effectiveness studies that emulate randomized trialsPhyo T Htoo, Robert J Glynn, Shirley Wang, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 3, 2023
Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia RiskPhyo T Htoo, Julie M Paik, Ethan Alt, et al.
JAMA Ophthalmology|December 5, 2024
Empagliflozin and the Risk of Retinopathy in Patients With Type 2 DiabetesHelen Tesfaye, Julie M Paik, Miin Roh, et al.
Journal of Clinical Epidemiology|September 28, 2025
Machine learning for predicting cardiovascular events in older adults with type 2 diabetes using Medicare claims and electronic health recordsPhyo T Htoo, Julie M Paik, Brendan M Everett, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
American Journal of Epidemiology|June 4, 2019
Counterpoint: Keeping the Demons at Bay When Handling Time-Varying Exposures-Beyond Avoiding Immortal Person-TimeJessie K Edwards, Phyo T Htoo, Til Stürmer
Annals of Internal Medicine|January 17, 2022
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, Phyo T Htoo, Brendan M Everett, et al.
Journal of the American Heart Association|February 8, 2022
Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart FailurePhyo T Htoo, John Buse, Matthew Cavender, et al.
European Journal of Clinical Pharmacology|May 12, 2016
Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursorsPhyo T Htoo, John B Buse, Mugdha Gokhale, et al.
Epidemiology (Cambridge, Mass.)|July 27, 2019
Renin-Angiotensin-Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare BeneficiariesPhyo T Htoo, Til Stürmer, Michele Jonsson-Funk, et al.
American Journal of Epidemiology|September 3, 2024
A systematic approach to evaluating instrumental variable assumptions: applied example of glucose-lowering medications and risk for hospitalized heart failure in older adultsPhyo T Htoo, Jessie K Edwards, Mugdha Gokhale, et al.
Pharmacoepidemiology and Drug Safety|October 25, 2023
Stratified analysis in comparative effectiveness studies that emulate randomized trialsPhyo T Htoo, Robert J Glynn, Shirley Wang, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 3, 2023
Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia RiskPhyo T Htoo, Julie M Paik, Ethan Alt, et al.
JAMA Ophthalmology|December 5, 2024
Empagliflozin and the Risk of Retinopathy in Patients With Type 2 DiabetesHelen Tesfaye, Julie M Paik, Miin Roh, et al.
Journal of Clinical Epidemiology|September 28, 2025
Machine learning for predicting cardiovascular events in older adults with type 2 diabetes using Medicare claims and electronic health recordsPhyo T Htoo, Julie M Paik, Brendan M Everett, et al.
Pageof 2